Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.57 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.53 |
| ▸ | KIF11 | P52732 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 7/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148317 | 0.84 | P2RY12 (0.63) | P2RY12MAOANPY5RKIF11KDM4E | |
| SCHEMBL148199 | 0.79 | SMN1; SMN2 (0.61) | P2RY12MAOANPY5RKDM4EMTNR1A | |
| SCHEMBL19308466 | 0.79 | P2RY12 (0.71) | P2RY12NPY5RKDM4EMTNR1AMTNR1B | |
| SCHEMBL22616930 | 0.78 | MAOA (0.86) | MAOAKIF11KDM4EMTNR1AMTNR1B | |
| SCHEMBL147307 | 0.77 | ROCK2 (0.73) | P2RY12MAOANPY5RKDM4EMTNR1A | |
| SCHEMBL3696476 | 0.76 | MAOA (0.64) | P2RY12MAOAKIF11KDM4EMTNR1A | |
| SCHEMBL148105 | 0.76 | RAB9A (0.62) | KIF11KDM4EKMT2AMAPT | |
| SCHEMBL4726206 | 0.75 | P2RY12 (0.73) | P2RY12NPY5RKDM4EMTNR1AMTNR1B | |
| SCHEMBL4726214 | 0.75 | P2RY12 (0.73) | P2RY12NPY5RKDM4EMTNR1AMTNR1B | |
| SCHEMBL22616916 | 0.74 | MAOA (0.62) | P2RY12MAOAKIF11KDM4EMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | P2RY12 1606/4885MAOA 3150/4885NPY5R 1492/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | P2RY12 1606/4885MAOA 3150/4885NPY5R 1492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.